UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Autologous Transplantation and Maintenance Therapy in Multiple Myeloma

The New England journal of medicine, 2014-09, Vol.371 (10), p.895-905

2014

Volltextzugriff (PDF)

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients

Blood, 2010-12, Vol.116 (23), p.4745-4753

2010

Volltextzugriff (PDF)

Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial

Haematologica (Roma), 2010-07, Vol.95 (7), p.1144-1149

2010

Volltextzugriff (PDF)

Autologous transplant for myeloma: when the old meets the new

Oncotarget, 2017-10, Vol.8 (53), p.90618-90619

2017

Volltextzugriff (PDF)

Immuno-oncologic approaches: CAR-T cells and checkpoint inhibitors

Clinical lymphoma, myeloma and leukemia, 2017-08, Vol.17 (8), p.471-478

2017

Volltextzugriff (PDF)

Pharmacophore modeling technique applied for the discovery of proteasome inhibitors

Expert opinion on drug discovery, 2014-08, Vol.9 (8), p.931-943

2014

Volltextzugriff (PDF)

Long Term Outcome of Lenalidomide-Dexamethasone (Rd) Vs Melphalan-Lenalidomide-Prednisone (MPR) Vs Cyclophosphamide-Prednisone-Lenalidomide (CPR) As Induction Followed By Lenalidomide-Prednisone (RP) Vs Lenalidomide (R) As Maintenance in a Community-Based Newly Diagnosed Myeloma Population: Updated Analysis of EMN01 Phase III Study

Blood, 2017-12, Vol.130 (Suppl_1), p.901-901

2017

Volltextzugriff (PDF)

Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCyd) in Elderly Newly Diagnosed Multiple Myeloma Patients: Results of a Phase 2 Study

Blood, 2015-12, Vol.126 (23), p.1828-1828

2015

Volltextzugriff (PDF)

Efficacy of a combination of human recombinant erythropoietin + 13‐cis‐retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes

British journal of haematology, 2009-02, Vol.144 (3), p.342-349

2009

Volltextzugriff (PDF)

A Phase II Study With Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) For Newly Diagnosed Multiple Myeloma

Blood, 2013-11, Vol.122 (21), p.685-685

2013

Volltextzugriff (PDF)

Retrospective Analysis on 290 Patients with Polycythemia Vera Referred to a Single Transfusion Centre: Diagnosis Revision According to WHO Criteria and Evaluation of Survival and Complications According to Prognostic Factors and Treatment

Blood, 2008-11, Vol.112 (11), p.5229-5229

2008

Volltextzugriff (PDF)

Sequential Therapy with IMID's in Relapsed-Refractory Multiple Myeloma Patients

Blood, 2009-11, Vol.114 (22), p.2888-2888

2009

Volltextzugriff (PDF)

A Maintenance Therapy with Differentiating Agents and Low-Dose Chemotherapy Increases Remission Duration and Survival in High Risk AML and MDS Patients

Blood, 2005-11, Vol.106 (11), p.4614-4614

2005

Volltextzugriff (PDF)

Persistent Telomeric Loss and Functional Impairment of Ph-Negative Hematopoiesis after Successful Treatment of Chronic Myelogenous Leukemia

Blood, 2008-11, Vol.112 (11), p.3183-3183

2008

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(38)

Sprache

Englisch
(38)
Japanisch
(2)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Autologous Transplantation and Maintenance Therapy in Multiple Myeloma

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients

Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial

Autologous transplant for myeloma: when the old meets the new

Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study

Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients

Immuno-oncologic approaches: CAR-T cells and checkpoint inhibitors

Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis

Pharmacophore modeling technique applied for the discovery of proteasome inhibitors

Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCyd) in Elderly Newly Diagnosed Multiple Myeloma Patients: Results of a Phase 2 Study

An Integrated Analysis of Cardio-Vascular Adverse Events of Carfilzomib, Cyclophosphamide and Dexamethasone in Elderly Newly Diagnosed Myeloma Patients Enrolled in 3 Phase I/II Trials

Real Life, Retrospective Analysis of Bortezomib Re-Use As Second Treatment for Relapsed Multiple Myeloma Patients Previously Exposed to Bortezomib-Based Therapies As First Line: The Rebound Study

Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study)

Doublet Vs Triplet Lenalidomide-Containing Regimens in Newly Diagnosed Myeloma Patients, Younger or Older Than 75 Years: Subgroup Analysis of a Phase III Study

Efficacy of a combination of human recombinant erythropoietin + 13‐cis‐retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes

A Randomized Phase 3 Trial Of Melphalan-Lenalidomide-Prednisone (MPR) Or Cyclophosphamide-Prednisone-Lenalidomide (CPR) Vs Lenalidomide Plus Dexamethsone (Rd) In Elderly Newly Diagnosed Multiple Myeloma Patients

A Phase II Study With Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) For Newly Diagnosed Multiple Myeloma

Cardio-vascular Toxicity in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients Treated With Carfilzomib, Cyclophosphamide and Dexamethasone: Results From an Integrated Analysis of 3 Phase I/II Trials

Retrospective Analysis on 290 Patients with Polycythemia Vera Referred to a Single Transfusion Centre: Diagnosis Revision According to WHO Criteria and Evaluation of Survival and Complications According to Prognostic Factors and Treatment

Efficacy and Safety of Once Weekly Bortezomib In Multiple Myeloma Patients

Ph-Negative Hematopoiesis Emerging After Successful Treatment of Chronic Myeloid Leukemia Displays Severe and Persistent Telomeric Loss Which Is Particularly Prominent in Patients with Acquired Cytogenetic Abnormalities

Sequential Therapy with IMID's in Relapsed-Refractory Multiple Myeloma Patients

A Maintenance Therapy with Differentiating Agents and Low-Dose Chemotherapy Increases Remission Duration and Survival in High Risk AML and MDS Patients

Persistent Telomeric Loss and Functional Impairment of Ph-Negative Hematopoiesis after Successful Treatment of Chronic Myelogenous Leukemia

Suchergebnisse filtern